Soluble epoxide hydrolase dimerization is required for hydrolase activity

Jonathan W. Nelson, Rishi M. Subrahmanyan, Sol A. Summers, Xiangshu Xiao, Nabil Alkayed

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Soluble epoxide hydrolase (sEH) plays a key role in the metabolic conversion of the protective eicosanoid 14,15-epoxyeicosatrienoic acid to 14,15-dihydroxyeicosatrienoic acid. Accordingly, inhibition of sEH hydrolase activity has been shown to be beneficial in multiple models of cardiovascular diseases, thus identifying sEH as a valuable therapeutic target. Recently, a common human polymorphism (R287Q) was identified that reduces sEH hydrolase activity and is localized to the dimerization interface of the protein, suggesting a relationship between sEH dimerization and activity. To directly test the hypothesis that dimerization is essential for the proper function of sEH, we generated mutations within the sEH protein that would either disrupt or stabilize dimerization. We quantified the dimerization state of each mutant using a split firefly luciferase protein fragment-assisted complementation system. The hydrolase activity of each mutant was determined using a fluorescence-based substrate conversion assay.Wefound that mutations that disrupted dimerization also eliminated hydrolase enzymatic activity. In contrast, a mutation that stabilized dimerization restored hydrolase activity. Finally, we investigated the kinetics of sEH dimerization and found that the human R287Q polymorphism was metastable and capable of swapping dimer partners faster than the WT enzyme. These results indicate that dimerization is required for sEH hydrolase activity. Disrupting sEH dimerization may therefore serve as a novel therapeutic strategy for reducing sEH hydrolase activity.

Original languageEnglish (US)
Pages (from-to)7697-7703
Number of pages7
JournalJournal of Biological Chemistry
Volume288
Issue number11
DOIs
StatePublished - Mar 15 2013

Fingerprint

Epoxide Hydrolases
Dimerization
Hydrolases
Polymorphism
Mutation
Protein Multimerization
Firefly Luciferases
Proteins
Eicosanoids
Dimers
Assays
Cardiovascular Diseases
Fluorescence

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Soluble epoxide hydrolase dimerization is required for hydrolase activity. / Nelson, Jonathan W.; Subrahmanyan, Rishi M.; Summers, Sol A.; Xiao, Xiangshu; Alkayed, Nabil.

In: Journal of Biological Chemistry, Vol. 288, No. 11, 15.03.2013, p. 7697-7703.

Research output: Contribution to journalArticle

Nelson, Jonathan W. ; Subrahmanyan, Rishi M. ; Summers, Sol A. ; Xiao, Xiangshu ; Alkayed, Nabil. / Soluble epoxide hydrolase dimerization is required for hydrolase activity. In: Journal of Biological Chemistry. 2013 ; Vol. 288, No. 11. pp. 7697-7703.
@article{e165fe07b1bb4ea29d920e943995419f,
title = "Soluble epoxide hydrolase dimerization is required for hydrolase activity",
abstract = "Soluble epoxide hydrolase (sEH) plays a key role in the metabolic conversion of the protective eicosanoid 14,15-epoxyeicosatrienoic acid to 14,15-dihydroxyeicosatrienoic acid. Accordingly, inhibition of sEH hydrolase activity has been shown to be beneficial in multiple models of cardiovascular diseases, thus identifying sEH as a valuable therapeutic target. Recently, a common human polymorphism (R287Q) was identified that reduces sEH hydrolase activity and is localized to the dimerization interface of the protein, suggesting a relationship between sEH dimerization and activity. To directly test the hypothesis that dimerization is essential for the proper function of sEH, we generated mutations within the sEH protein that would either disrupt or stabilize dimerization. We quantified the dimerization state of each mutant using a split firefly luciferase protein fragment-assisted complementation system. The hydrolase activity of each mutant was determined using a fluorescence-based substrate conversion assay.Wefound that mutations that disrupted dimerization also eliminated hydrolase enzymatic activity. In contrast, a mutation that stabilized dimerization restored hydrolase activity. Finally, we investigated the kinetics of sEH dimerization and found that the human R287Q polymorphism was metastable and capable of swapping dimer partners faster than the WT enzyme. These results indicate that dimerization is required for sEH hydrolase activity. Disrupting sEH dimerization may therefore serve as a novel therapeutic strategy for reducing sEH hydrolase activity.",
author = "Nelson, {Jonathan W.} and Subrahmanyan, {Rishi M.} and Summers, {Sol A.} and Xiangshu Xiao and Nabil Alkayed",
year = "2013",
month = "3",
day = "15",
doi = "10.1074/jbc.M112.429258",
language = "English (US)",
volume = "288",
pages = "7697--7703",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "11",

}

TY - JOUR

T1 - Soluble epoxide hydrolase dimerization is required for hydrolase activity

AU - Nelson, Jonathan W.

AU - Subrahmanyan, Rishi M.

AU - Summers, Sol A.

AU - Xiao, Xiangshu

AU - Alkayed, Nabil

PY - 2013/3/15

Y1 - 2013/3/15

N2 - Soluble epoxide hydrolase (sEH) plays a key role in the metabolic conversion of the protective eicosanoid 14,15-epoxyeicosatrienoic acid to 14,15-dihydroxyeicosatrienoic acid. Accordingly, inhibition of sEH hydrolase activity has been shown to be beneficial in multiple models of cardiovascular diseases, thus identifying sEH as a valuable therapeutic target. Recently, a common human polymorphism (R287Q) was identified that reduces sEH hydrolase activity and is localized to the dimerization interface of the protein, suggesting a relationship between sEH dimerization and activity. To directly test the hypothesis that dimerization is essential for the proper function of sEH, we generated mutations within the sEH protein that would either disrupt or stabilize dimerization. We quantified the dimerization state of each mutant using a split firefly luciferase protein fragment-assisted complementation system. The hydrolase activity of each mutant was determined using a fluorescence-based substrate conversion assay.Wefound that mutations that disrupted dimerization also eliminated hydrolase enzymatic activity. In contrast, a mutation that stabilized dimerization restored hydrolase activity. Finally, we investigated the kinetics of sEH dimerization and found that the human R287Q polymorphism was metastable and capable of swapping dimer partners faster than the WT enzyme. These results indicate that dimerization is required for sEH hydrolase activity. Disrupting sEH dimerization may therefore serve as a novel therapeutic strategy for reducing sEH hydrolase activity.

AB - Soluble epoxide hydrolase (sEH) plays a key role in the metabolic conversion of the protective eicosanoid 14,15-epoxyeicosatrienoic acid to 14,15-dihydroxyeicosatrienoic acid. Accordingly, inhibition of sEH hydrolase activity has been shown to be beneficial in multiple models of cardiovascular diseases, thus identifying sEH as a valuable therapeutic target. Recently, a common human polymorphism (R287Q) was identified that reduces sEH hydrolase activity and is localized to the dimerization interface of the protein, suggesting a relationship between sEH dimerization and activity. To directly test the hypothesis that dimerization is essential for the proper function of sEH, we generated mutations within the sEH protein that would either disrupt or stabilize dimerization. We quantified the dimerization state of each mutant using a split firefly luciferase protein fragment-assisted complementation system. The hydrolase activity of each mutant was determined using a fluorescence-based substrate conversion assay.Wefound that mutations that disrupted dimerization also eliminated hydrolase enzymatic activity. In contrast, a mutation that stabilized dimerization restored hydrolase activity. Finally, we investigated the kinetics of sEH dimerization and found that the human R287Q polymorphism was metastable and capable of swapping dimer partners faster than the WT enzyme. These results indicate that dimerization is required for sEH hydrolase activity. Disrupting sEH dimerization may therefore serve as a novel therapeutic strategy for reducing sEH hydrolase activity.

UR - http://www.scopus.com/inward/record.url?scp=84875180857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875180857&partnerID=8YFLogxK

U2 - 10.1074/jbc.M112.429258

DO - 10.1074/jbc.M112.429258

M3 - Article

C2 - 23362272

AN - SCOPUS:84875180857

VL - 288

SP - 7697

EP - 7703

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 11

ER -